Quarterly ResultMay 14, 2026, 08:42 AM
GRI Bio Q1 Results; GRI-0621 Phase 2a Data Reinforce IPF Potential
AI Summary
GRI Bio reported its first quarter 2026 financial results and provided a corporate update, highlighting positive Phase 2a data for GRI-0621 in Idiopathic Pulmonary Fibrosis (IPF). The data reinforced GRI-0621's differentiated therapeutic potential, showing improved tolerability with zero cough and significantly reduced treatment-related diarrhea, alongside improvements in lung function. The company also advanced GRI-0803 toward IND-enabling activities and strengthened its balance sheet, with approximately $11.0 million in cash and a runway into the second quarter of 2027.
Key Highlights
- GRI-0621 Phase 2a data showed zero cough in active arm vs. 25% in placebo.
- GRI-0621 reduced treatment-related diarrhea by 61% (13% vs. 33% placebo).
- Exploratory pulmonary function showed +99 mL FVC improvement overall with GRI-0621.
- Cash and cash equivalents totaled approximately $11.0 million as of March 31, 2026.
- Existing cash resources are sufficient to fund planned operations into Q2 2027.
- Net loss for Q1 2026 was approximately $2.0 million, down from $3.0 million in Q1 2025.
- R&D expenses decreased to approximately $0.4 million in Q1 2026 from $1.6 million in Q1 2025.
- Generated approximately $6.8 million in gross proceeds from At The Market facility in Q1 2026.
Price Impact
More from GRI